PUBH 3100 Week 4 Natural History Profile Example

Four Stages of Type 2 Diabetes and What One Prevention Trial Settles About the Silent Second: A Natural History Profile From Susceptibility to Untreated Complications

Student Name

Walden University

PUBH 3100: Human Disease and Prevention

Instructor Name

Month Day, Year

Four Stages of Type 2 Diabetes and What One Prevention Trial Settles About the Silent Second: A Natural History Profile From Susceptibility to Untreated Complications

The Natural History Framework

The natural history of a disease describes its course in a person without intervention: a stage of susceptibility before disease begins, a stage of subclinical disease when changes are present but unnoticed, a stage of clinical disease when signs and symptoms appear, and a stage of outcomes such as complications, disability or death. Placing a disease on this timeline shows where prevention can act. This profile takes type 2 diabetes through all four stages but gives the second the most space, because that is where the strongest prevention evidence sits.

Stage 1: Susceptibility

Before any change in blood glucose, some people are more likely than others to develop type 2 diabetes. Family history, excess body fat, especially around the abdomen, physical inactivity, older age and a history of diabetes during pregnancy all raise risk. At this stage, glucose regulation is normal, but the conditions for later failure are present. As the Week 2 brief explained, diabetes develops when the pancreas can no longer produce enough insulin to overcome the body's resistance to it; susceptibility describes the factors that increase resistance or limit the pancreas's reserve.

Stage 2: The Years When Nothing Is Felt

What Happens

Long before diagnosis, blood glucose begins to rise. Many people pass through a state called prediabetes, defined by fasting glucose or post-meal glucose above normal but below the diabetes threshold, or by a modestly raised hemoglobin A1c. A review of prediabetes described it as a high-risk state, with many people progressing to diabetes within years, while others remain stable or return to normal (Tabák et al., 2012). People in this stage almost always feel well, so the stage is found only by testing.

The Prevention Trial Placed Here

The Diabetes Prevention Program enrolled adults with excess weight and raised fasting and post-meal glucose, that is, people in stage 2, and randomly assigned them to an intensive lifestyle program, the drug metformin or a placebo. After roughly three years on average, new diabetes was 58% less common in the lifestyle arm and 31% less common in the metformin arm than with placebo (Diabetes Prevention Program Research Group, 2002). Because the trial was randomized, these differences can be attributed to the interventions rather than to differences between groups.

What the Trial Genuinely Settles

The trial settles that, among people with prediabetes who meet its entry criteria, an intensive lifestyle program delays the diagnosis of diabetes. Long-term follow-up adds an important qualification. After an average of 15 years, the lifestyle group's diabetes incidence was 27% lower and the metformin group's 18% lower than the placebo group's, with the differences narrowing over time; by year 15, 55% of the lifestyle group, 56% of the metformin group and 62% of the placebo group had developed diabetes (Diabetes Prevention Program Research Group, 2015).

What It Does Not Settle

Delay is not the same as prevention for life. The trial also did not show, across the whole cohort, a significant difference in the combined measure of small-vessel complications at 15 years, although women in the lifestyle group had a lower prevalence. The trial's participants were volunteers willing to attend an intensive program, so the results may not transfer directly to community programs with less contact. And the trial tells us about people already in stage 2, not about how to keep people from reaching it.

Stage 3: Clinical Disease

Diabetes is diagnosed when blood glucose crosses defined thresholds. Some people notice thirst, frequent urination or fatigue, but many are diagnosed by routine testing without symptoms. By diagnosis, the pancreas has often lost much of its insulin-producing capacity, as autopsy studies described in Week 2 suggest.

Stage 4: What Untreated Illness Reaches

Without control of glucose, blood pressure and cholesterol, diabetes harms the tiny vessels of the retina, kidney and peripheral nerves and hastens plaque in the large arteries. The outcomes include vision loss, kidney failure, foot ulcers and amputation, heart attack and stroke. These complications develop over years, which is why the earlier stages matter so much, and why the same person may pass through all four stages over two or three decades.

Who Is in Stage 2

Prediabetes is common, which makes the second stage a population problem rather than an individual one. Because people in this stage feel well, they are found only when someone tests them, and testing depends on access to care and on clinicians' habits. People without regular care are less likely to learn that their glucose is rising and therefore less likely to be offered the kind of lifestyle program tested in the trial. A prevention strategy built only on finding and treating people in stage 2 will reach those already connected to care first. That is one reason the profile treats the trial's results as necessary but not sufficient: they show what works once people are found, not how to find them or how to keep the next cohort from arriving in stage 2 at all.

Where Prevention Can Act

Table 1

Natural History of Type 2 Diabetes and Points for Prevention

Note. Prepared for this profile; prevention levels follow the stages above.

Summary

Type 2 diabetes passes through a long silent stage that can be detected only by testing. A randomized trial placed in that stage shows that intensive lifestyle change delays diabetes substantially for several years and modestly over fifteen, without settling whether it prevents complications for everyone. The natural history suggests prevention should begin before stage 2, where trial evidence is thinner and population measures matter more.

References

Diabetes Prevention Program Research Group. (2002). Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. The New England Journal of Medicine, 346(6), 393-403. https://doi.org/10.1056/NEJMoa012512

Diabetes Prevention Program Research Group. (2015). Long-term effects of lifestyle intervention or metformin on diabetes development and microvascular complications over 15-year follow-up: The Diabetes Prevention Program Outcomes Study. The Lancet Diabetes & Endocrinology, 3(11), 866-875. https://doi.org/10.1016/S2213-8587(15)00291-0

Tabák, A. G., Herder, C., Rathmann, W., Brunner, E. J., & Kivimäki, M. (2012). Prediabetes: A high-risk state for diabetes development. The Lancet, 379(9833), 2279-2290. https://doi.org/10.1016/S0140-6736(12)60283-9